3-methoxy-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid | 459842-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-methoxy-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid
• 英文别名: 4-[[4,5-Dimethyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]-3-methoxybenzoic acid
• CAS: 459842-10-5
• 化学式: C₂₆H₃₀N₂O₆S
• 分子量: 498.6
• InChiKey: TWMVCGIHQSAHEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Remedies for depression containing ep1 antagonist as the active ingredient
  申请人：——

  公开号：US20040082653A1

  公开（公告）日：2004-04-29

  A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP 1 receptor which a prostaglandin E 2 receptor subtype. EP 1 antagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

  一种用于治疗和/或预防抑郁症的药物组合物，包括一种具有EP1受体拮抗活性的化合物，该受体是前列腺素E2受体亚型。EP1拮抗剂对于治疗抑郁症很有用，例如内源性抑郁症，反应性抑郁症，耐受性抑郁症，神经学抑郁状态，脑器质性心境障碍的抑郁状态。
• N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same
  申请人：Naganawa Atsushi

  公开号：US20050124672A1

  公开（公告）日：2005-06-09

  An N-phenylarylsulfonylamide compound of formula (I) (R 1 is COOH etc.; R 2 is hydrogen, methyl, etc.; R 3 and R 4 are a combination of methyl and methyl, etc.; R 5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E 2 receptor, especially an EP 1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.

  化合物的化学式为(I)，其中N-苯基磺酰胺化合物（R1为COOH等；R2为氢，甲基等；R3和R4为甲基和甲基的组合等；R5为异丙基等；Ar为噻唑基，吡啶基，5-甲基-2-呋喃基，每个基团可选地取代甲基；n为零或1），是该化合物的合成中间体，以及其制备方法。化合物(I)与前列腺素E2受体结合，特别是EP1亚型受体，并拮抗它。它受蛋白结合的影响较小，因此具有令人满意的体内活性。因此，它被认为是一种有用的镇痛剂，退热剂，治疗频尿和/或下尿路疾病综合征或抗肿瘤剂的药物。
• N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation
  申请人：Naganawa Atsushi

  公开号：US20060030713A1

  公开（公告）日：2006-02-09

  An N-phenylarylsulfonylamide compound of formula (I) (R 1 is COOH etc.; R 2 is hydrogen, methyl, etc.; R 3 and R 4 are a combination of methyl and methyl, etc.; R 5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E 2 receptor, especially an EP 1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.

  公式（I）的N-苯基磺酰胺化合物（其中R1为COOH等；R2为氢，甲基等；R3和R4为甲基和甲基的组合等；R5为异丙基等；Ar为噻唑基，吡啶基，5-甲基-2-呋喃基，每个都可以选择性地用甲基取代；n为零或1），用于该化合物的合成中间体以及其制备方法。公式（I）的化合物结合到前列腺素E2受体，特别是EP1亚型受体，并对其产生拮抗作用。它受蛋白结合的影响较小，因此具有令人满意的体内活性。因此，它被认为是一种有用的镇痛剂，退烧剂，治疗排尿频繁和/或下尿路疾病综合征或抗肿瘤剂的药物。
• N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION
  申请人：NAGANAWA Atsushi

  公开号：US20100041708A1

  公开（公告）日：2010-02-18

  An N-phenylarylsulfonylamide compound of formula (I) (R 1 is COOH etc.; R 2 is hydrogen, methyl, etc.; R 3 and R 4 are a combination of methyl and methyl, etc.; R 5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E 2 receptor, especially an EP 1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.

  化合物(I)是一种N-苯基磺酰胺化合物，其化学式为（R1为COOH等；R2为氢，甲基等；R3和R4为甲基和甲基的组合等；R5为异丙基等；Ar为噻唑基，吡啶基，5-甲基-2-呋喃基，每个基团可选地被甲基取代；n为零或1），用于该化合物的合成中间体和其制备方法。化合物(I)与前列腺素E2受体结合，特别是EP1亚型受体，并拮抗其作用。它受蛋白结合的影响较小，因此具有令人满意的体内活性。因此，它被认为是一种有用的镇痛剂，退烧剂，用于治疗多尿和/或下尿路疾病综合症或抗肿瘤剂的药剂。
• REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1369129A1

  公开（公告）日：2003-12-10

  A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP1 receptor which a prostaglandin E2 receptor subtype. EP1 antagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

  一种用于治疗和/或预防抑郁症的药物组合物，包含一种对前列腺素 E2 受体亚型的 EP1 受体具有拮抗活性的化合物。 EP1拮抗剂可用于治疗抑郁症，例如内源性抑郁症、反应性抑郁症、气候性抑郁症、神经性抑郁状态、脑器质性精神障碍的抑郁状态。